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South Africa has the highest incidence and mortality rates of tu-
berculosis (TB) in the world.1 Just under 2% of newly diagnosed 
TB and 6.7% of re-treatment TB patients have multidrug-resistant 
TB (MDR TB),2 translating into almost 7 000 drug-resistant 
TB cases per year, with the highest proportion in 2008 from 
KwaZulu-Natal.1 MDR TB is defined as TB resistant to isoniazid 
and rifampicin.3 Failure of first-line TB regimens caused by poor 
adherence to drug-sensitive TB treatment is the most impor-
tant factor in the development of MDR TB; the unavailability 
of effective TB drugs also contributes to this failure.3 As MDR 
TB symptoms and method of spread are the same as those of 
drug-sensitive TB, differentiation is impossible without further 
investigations.3 MDR TB can be identified by culturing sputum 
samples with drug sensitivity testing (DST) and by line probe as-
says (LPAs). Culture and DST take 8 weeks or longer, while LPAs 
can give a result in hours.2 The National Department of Health 
(NDoH) guidelines require that patients diagnosed with MDR 
TB be referred to a specialised treatment centre for initiation of 
effective therapy.3 There are only a few such specialised centres 
located in South Africa’s main cities.3 The NDoH recognises that 
centralised management of MDR TB faces challenges that cause 
treatment delays, increased patient morbidity and mortality, and 
MDR TB nosocomial transmission.4 We aimed to profile the 
patients being referred with MDR TB to a centralised treatment 
centre and investigate the time from the collection of sputum 
samples for DST to the initiation of effective therapy.
Methods
The study hospital is a centralised treatment and referral centre for 
MDR TB in KwaZulu-Natal. The referral prerequisite is confirmation 
of MDR TB by culture and DST. Although LPAs are used, this has not 
been integrated into the NDoH treatment guidelines, and therefore 
a culture and DST is still the gold standard for diagnosis.3,5,6 Patients 
referred with results using tests other than culture and DST are 
assessed, and treatment is only initiated with confirmed results.3 
Patients are admitted if they do not have a local clinic to receive their 
injections, are very ill or do not have social support to enable outpatient 
treatment. For outpatient treatment, a step-down facility or a local 
clinic close to home is required to supervise treatment. Both inpatient 
and outpatient facilities have long waiting lists of patients awaiting 
treatment.
We included all patients referred to the hospital in 2010 with a DST 
result confirming MDR pulmonary TB that qualified for treatment. 
Patients who presented with extrapulmonary MDR TB, mono- or 
polyresistant TB (not to isoniazid and rifampicin) and who did not 
present with results, were excluded. On average during 2010, 100 
patients per month were initiated on treatment.
A sample size of 200, representing 20% of the study population, was 
chosen. All the charts of patients initiated on treatment in 2 random 
months were analysed. Data from patient records and the hospital 
database were gathered on a data collation sheet and entered on a 
Microsoft Excel  spreadsheet and analysed using the SPSS programme.
Descriptive analysis involved mean, standard deviation and range 
in normally distributed quantitative variables. As this was a descriptive 
study, no hypothesis was tested. The time interval (in weeks) between 
the collection of the sputum sample for culture and DST and the 
start of treatment was calculated. A delay was defined as the interval 
between sending sputum for DST testing and initiation of effective 
treatment exceeding 8 weeks; an acceptable range is between 6 and 8 
weeks.3,5
Ethical approval was obtained from the Biomedical Research Ethics 
Committee of the University of KwaZulu-Natal and the Research 
Ethics Committee of the hospital where the study was conducted.
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Background. According to the National Department of Health 
(NDoH) guidelines, patients diagnosed with multidrug-resistant 
tuberculosis (MDR TB) must be referred to a specialised treatment 
centre for initiation of effective therapy. MDR TB is difficult to 
diagnose and the centralised referral model is beset with challenges 
that contribute to treatment delays, increased patient morbidity 
and mortality, and MDR TB nosocomial transmission. Culture and 
drug sensitivity testing (DST) takes 8 weeks or longer to obtain 
results while line probe assays (LPAs) can give a result in hours. 
LPAs and the GeneXpert MTB/Rif (GX) are ground-breaking 
discoveries for TB diagnosis. However, they are not easily accessible 
or available to those needing it, so culture and sensitivity testing 
remains the gold standard for diagnosis.
Aim. This study aimed to assess the delay in the initiation of 
MDR TB treatment and profiled the patients being referred to a 
specialised drug-resistant treatment centre in KwaZulu-Natal.
Results. Of all the patients, 75% referred showed a mean delay of 
12.4 weeks from the date of sputum collection for culture and drug 
sensitivity testing to the start of treatment. Most of the patients were 
symptomatic for TB and HIV-positive.
Discussion. Our findings suggest that current policy on the 
initiation of effective treatment needs urgent revision. Staff should 
be appropriately trained in LPA and GX technology to reduce delays 
in initiating treatment for MDR TB. The NDoH’s plans for rapid 
diagnosis and reducing the treatment burden on centralised MDR 
TB management facilities are in the early phases of implementation 
and will take years to achieve favourable and significant outcomes.
Conclusion. There is a significant delay in initiating definitive 
management for MDR TB.
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Results
In total, 1 158 patients were referred to the study hospital in 2010; 207 
patient charts were reviewed of which 21 were excluded because they 
did not meet the inclusion criteria. Most patients were black, aged 
between 19 and 50 years, with an almost equal representation of men 
and women. Patients were mostly unemployed and symptomatic for 
TB with at least one previous TB episode. MDR TB contact history 
was poorly documented (Table 1). Of the patients, 69% were HIV-
positive, on antiretroviral therapy (ART) (75%) with CD4 counts 
<250 (59%); 74 (40%) were managed as inpatients, 101 (54%) as 
outpatients, and 11 (6%) were placed on the surveillance programme. 
This programme applies to patients referred with confirmatory DST 
results but who were not considered to have active MDR TB disease. 
Patients from the eThekwini municipality comprised 47%, while 
63% were from neighbouring districts; 111 (59.7%) were on standard 
TB regimens at the time of referral, while 75 (40.3%) were not on 
treatment. The mean delay from the date of collection of the sputum 
sample for culture and DST to initiation of treatment was 12.36 weeks 
(range 3 - 30 weeks) (Table 2).
Discussion
We aimed to investigate the time from the collection of sputum 
samples for DST to the initiation of effective therapy. A similar study 
in Cape Town showed an average of 5 - 6 weeks’ delay in initiation 
of treatment for patients with MDR TB.7 However, in our study 131 
(75%) of patients experienced delays of up to 22 weeks, and only 
44 (25%) patients were started on treatment without a significant 
delay. This is of concern, since almost 90% of all patients seen were 
coughing. Delaying treatment for patients who are actively coughing 
perpetuates the spread of MDR TB. It was previously believed that 
resistant strains of TB were not virulent enough for high transmission 
rates and that infection control was therefore not important.8 
However, human-to-human spread of MDR TB is more common than 
anticipated, and the disease spreads while patients await diagnosis 
and initiation of treatment.8 In the Western Cape, 90% of all tested 
drug-resistant TB cases were smear-positive, suggesting that person-
to-person spread of MDR TB is a significant risk.9 Patients who are 
on ineffective drug regimens fuel TB drug resistance.3 South Africa 
has limited data on reasons for delays associated with the initiation 
of  treatment for MDR TB, and more research is needed. Studies 
on drug-sensitive TB suggest that healthcare workers, systems and 
patient factors all contribute to delayed initiation of treatment.10,11 As 
part of the solution, the NDoH has suggested a decentralised model 
of MDR TB management; this may help to reduce the number of days 
between diagnosis and treatment initiation by increasing the number 
of treatment centres for referral, which will in turn reduce the 
transmission of disease.4 To meet this need, nurse-initiated treatment 
programmes, which are currently successful for HIV management 
throughout the world, are being strongly considered by the NDoH to 
integrate MDR TB and HIV management in communities.4
The World Health Organization (WHO) endorsed the use of LPAs 
for detecting TB and MDR TB, which decreases time to diagnosis 
from weeks to a day, and which requires highly trained technical 
staff.6 The GeneXpert MTB/Rif (GX) molecular test assay provides 
TB case detection and rifampicin-resistance testing with results being 
available from raw sputum in about 2 hours and does not require 
highly trained personnel.12 Availability of this test will enable the 
rapid detection of MDR TB for point-of-care management of patients 
who can be referred for treatment timeously. In 2009, the NDoH set 
a target to roll out 20 new secondary laboratory services by the end 
of 2010 to achieve rapid diagnosis of MDR TB.8 However, only 11 
laboratories were established by the end of 2010.8 In March 2011, the 
NDoH approved 25 sites in South Africa’s high-burden districts for 
GX to be installed; however, by the end of 2011, only 1 site had been 
fully capacitated.12 Lack of capacity at all sites for rapidly diagnosing 
Table 1. Description of sample
Total (N=186) %
Gender
Male
Female
97
89
52
48
Age
<12 years
12 - 18 years
19 - 50 years
>51 years
5
17
145
19
2.8
9
78
10.2
Race
Black
Indian
White
182
3
1
97.8
1.6
0.6
Employment status
Employed
Unemployed
31
155
16.7
83.3
MDR TB past exposure
MDR contact
Occupational exposure
Unknown
22
3
161
11.8
1.6
86.6
Previous TB infection
No previous TB
1 episode
2 episodes
3 episodes
≥4 episodes
31
71
63
19
2
16.6
38.1
33.9
10.2
1.2
Symptomatic cough
No cough
Cough
17
169
9.2
90.8
HIV status
Negative
Positive
Unknown
47
128
11
25.2
68.9
5.9
Table 2. Time from the date of collection of sputum to start of 
treatment
Cumulative 
weeks*
No. of months 
delay (at 4-week 
intervals)† N=175 %
0 - 8 0 44 25
9 - 12 1 54 31
13 - 16 2 42 24
17 - 20 3 21 12
21 - 24 4 7 4
25 - 28 5 5 2.9
29 - 30 >5 2 1.1
*Time interval between the collection date of sputum sample for DST and start date of 
treatment in weeks.
†The average expected time interval from collection of the sputum sample for culture and 
DST and receiving a result is 6 - 8 weeks. For the purposes of this study, a delay is defined as 
a time period exceeding 8 weeks.
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MDR TB is compounded by the current policy of only treating MDR 
TB based on DST, regardless of the results from the GX. This policy 
completely negates the advantages of using the GX to diagnose 
MDR TB. Although documentation was poor, 22 patients (11.8%) 
gave a history of a known MDR TB contact. There were 31 patients 
(16%) with primary MDR TB (i.e. no previous TB history), with an 
incidence of 55% in women and 45% in men. The high number of 
primary MDR TB patients in the sample is of concern, as it is much 
higher than the 1.8% of the MDR TB population estimated by the 
NDoH. Ours is a small sample but, if representative, it warrants 
further investigation. Based on this finding, healthcare workers must 
ensure that all high-risk patients presenting with TB are screened 
for MDR TB as per NDoH guidelines.3 In particular, HIV-positive 
patients with symptoms of TB need screening for MDR TB, as 71% 
of our patients with primary MDR TB were HIV-positive, with 59% 
of them having a CD4 count <250. HIV-positive patients have an 8.4 
times higher risk of harbouring MDR TB strains than HIV-negative 
patients.2 A small percentage of patients did not know their HIV 
status; a larger percentage of the HIV-positive patients did not know 
their CD4 count; and a significant number of HIV-positive patients 
were not on ART. This suggests that gaps remain in the South African 
HIV counselling and testing programme. All patients with MDR TB 
should be on ART, according to the NDoH.13
Conclusion
There is a significant time delay in the initiation of effective 
treatment for patients with MDR TB. Most of the patients who 
presented to the clinic were coughing, thereby fuelling the spread 
of community-transmitted MDR TB. LPAs and the GX are ground-
breaking discoveries for TB diagnosis; however, they are not yet easily 
accessible or available to those in need of it. In view of the findings 
from this study, current policy on the initiation of effective treatment 
based on these results will need to be revised urgently. In addition, 
all staff should receive appropriate training if the newer technology is 
to reduce delays in initiation of treatment for MDR TB. The NDoH’s 
proposed plans for rapid diagnosis and reducing the treatment 
burden on centralised MDR TB management facilities are all in the 
early phases of implementation, and it will take many more years to 
achieve a favourable and significant outcome.
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